MK-2206 2HCl is primarily used in cancer research due to its ability to inhibit the Akt signaling pathway, which plays a key role in cell survival and proliferation. It has shown potential in preclinical studies for treating various cancers, including breast, prostate, and lung cancers, especially in tumors with hyperactive PI3K/Akt pathways. Researchers use it to sensitize cancer cells to chemotherapy and radiation by suppressing Akt-mediated resistance mechanisms. Its application is mainly in experimental settings to evaluate targeted therapy approaches and combination treatments in oncology.